GlassScriptPhysician profile
Ravi Choxi
NPI 1184112492
$39,305.13
in general payments reported to CMS, 2019-2025
16 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,664 · 2023: $589 · 2024: $14K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $19K · Travel and Lodging: $7,125 · Food and Beverage: $6,211 · Education: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $19,437.50 |
| Travel and Lodging | $7,125.20 |
| Food and Beverage | $6,210.75 |
| Education | $867.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,038.88 | 2022-2025 | Ensite, Assurity, Tacticath |
| Medtronic, INC. | $8,964.40 | 2022-2025 | Cobalt Dr Mri Surescan, Onyx Frontier, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $6,045.75 | 2024-2025 | General - Brady, Watchman Access System, Watchman |
| Biosense Webster, INC. | $1,868.02 | 2024-2025 | Carto 3 |
| Biotronik INC. | $1,475.18 | 2024-2025 | Amvia Edge |
| E.R. Squibb & Sons, L.L.C. | $314.99 | 2022-2024 | Camzyos, Eliquis |
| Pfizer INC. | $135.45 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $111.14 | 2022-2023 | Xarelto |
| Abiomed | $66.56 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $65.52 | 2023-2024 | Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.94 | 2022-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $53.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $36.36 | 2023 | |
| Cardiva Medical, INC. | $29.96 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Edwards Lifesciences Corporation | $21.06 | 2023 | Sapien 3 Ultra Resilia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Choxi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.